siltuximab + bortezomib

This combination consists of **siltuximab**, a chimeric monoclonal antibody that binds human interleukin-6 (IL-6) and prevents it from interacting with its receptors, thereby inhibiting IL-6-driven proliferation of lymphocytes[2][3][4][6], and **bortezomib**, a small molecule proteasome inhibitor that reversibly blocks the chymotryptic-like activity of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, and suppression of the NF-κB signaling pathway[5]. The combination has been mainly studied in the context of **relapsed/refractory multiple myeloma**, where it showed an increased response rate but did not improve progression-free survival or overall survival compared to bortezomib alone[1][3][9][10]. Siltuximab is developed by blocking IL-6, important in multiple myeloma pathophysiology[2][3][4][9]. Bortezomib is an established agent for multiple myeloma and mantle cell lymphoma[5].

Brand names

Bortezomib Fresenius KabiBoruzu

Other names

siltuximabbortezomib